牛牛AI助手已提取核心信息
Eli Lilly and Company (Lilly) announced a series of significant achievements and strategic decisions in its 2023 Annual Meeting of Shareholders notice. The company reported regulatory approvals for new medicines, including Omvoh for ulcerative colitis, Jaypirca for MCL or CCL, and Zepbound for obesity. Lilly also highlighted results from the Trailblazer-ALZ 2 study indicating a slowdown in Alzheimer's disease progression. The company delivered strong shareholder returns through share price appreciation and dividends and donated over $4 billion in medicines to charitable organizations. Lilly's 30x30 goal aims to improve healthcare for 30 million people in resource-limited settings by 2030. The company engaged with investors on topics like drug pricing, global product access, and environmental, social, and governance issues. Management proposals at the 2024 annual meeting will include eliminating the classified board structure and supermajority voting requirements in the articles of incorporation. The 2024 Annual Meeting of Shareholders will be held virtually on May 6, 2024, at 8:30 a.m. EDT.
Eli Lilly and Company (Lilly) announced a series of significant achievements and strategic decisions in its 2023 Annual Meeting of Shareholders notice. The company reported regulatory approvals for new medicines, including Omvoh for ulcerative colitis, Jaypirca for MCL or CCL, and Zepbound for obesity. Lilly also highlighted results from the Trailblazer-ALZ 2 study indicating a slowdown in Alzheimer's disease progression. The company delivered strong shareholder returns through share price appreciation and dividends and donated over $4 billion in medicines to charitable organizations. Lilly's 30x30 goal aims to improve healthcare for 30 million people in resource-limited settings by 2030. The company engaged with investors on topics like drug pricing, global product access, and environmental, social, and governance issues. Management proposals at the 2024 annual meeting will include eliminating the classified board structure and supermajority voting requirements in the articles of incorporation. The 2024 Annual Meeting of Shareholders will be held virtually on May 6, 2024, at 8:30 a.m. EDT.
礼来公司（Lilly）在其2023年年度股东大会通知中宣布了一系列重大成就和战略决策。该公司报告了监管部门对新药的批准，包括用于溃疡性结肠炎的Omvoh、用于MCL或CCL的Jaypirca和用于肥胖的Zepbound。礼来还强调了Trailblazer-ALZ 2研究的结果，该结果表明阿尔茨海默氏病进展放缓。该公司通过股价升值和分红为股东带来了丰厚的回报，并向慈善组织捐赠了超过40亿美元的药品。礼来公司的30x30目标旨在到2030年改善资源有限环境中3000万人的医疗保健。该公司就药品定价、全球产品准入以及环境、社会和治理问题等话题与投资者进行了接触。2024年年会上的管理层提案将包括取消机密董事会结构和公司章程中的绝大多数投票要求。2024年年度股东大会将在美国东部时间2024年5月6日上午8点30分虚拟举行。
礼来公司（Lilly）在其2023年年度股东大会通知中宣布了一系列重大成就和战略决策。该公司报告了监管部门对新药的批准，包括用于溃疡性结肠炎的Omvoh、用于MCL或CCL的Jaypirca和用于肥胖的Zepbound。礼来还强调了Trailblazer-ALZ 2研究的结果，该结果表明阿尔茨海默氏病进展放缓。该公司通过股价升值和分红为股东带来了丰厚的回报，并向慈善组织捐赠了超过40亿美元的药品。礼来公司的30x30目标旨在到2030年改善资源有限环境中3000万人的医疗保健。该公司就药品定价、全球产品准入以及环境、社会和治理问题等话题与投资者进行了接触。2024年年会上的管理层提案将包括取消机密董事会结构和公司章程中的绝大多数投票要求。2024年年度股东大会将在美国东部时间2024年5月6日上午8点30分虚拟举行。
有用
没用